Bristol-Myers Squibb Company
Research Bristol-Myers Squibb Company (BMY) on Bullrun: valuation model: 13.8% undervalued, market cap USD 120.78B, P/E 13.0, dividend yield 4.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBMY
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Valuation signal13.8% undervalued
- Market capUSD 120.78B
- P/E13.0
- Dividend yield4.4%
- Financial periodQ2 2026
- RevenueUSD 12.97B
- Net incomeUSD 3.32B
- Free cash flowUSD 3.09B
- Gross margin71.3%
Valuation Snapshot
Bullrun's latest valuation model marks Bristol-Myers Squibb Company as 13.8% undervalued; latest market cap is USD 120.78B; P/E is 13.0; dividend yield is 4.4%.
Peer valuation comparison
Latest P/E is 13.02x versus a Healthcare sector median of 24.61x (47.1% below).
Latest dividend yield is 4.38% versus a Healthcare sector median of 1.84% (138.0% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 48.19B | USD 7.05B | USD 12.85B | 71.1% | 3.46 | USD 10.21B | USD 45.11B | USD 18.47B |
| FY2024 | USD 48.30B | -USD 8.95B | USD 13.94B | 71.1% | -4.41 | USD 10.35B | USD 49.65B | USD 16.34B |
| FY2023 | USD 45.01B | USD 8.03B | USD 12.65B | 76.2% | 3.86 | USD 11.46B | USD 39.77B | USD 29.43B |
| FY2022 | USD 46.16B | USD 6.33B | USD 11.95B | 78.0% | 2.95 | USD 9.12B | USD 39.32B | USD 31.06B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 120.78B | 13.0 | 4.3% | 2.52 |
| 2025 | 2025-12-31 | USD 109.81B | 15.6 | 4.6% | 2.48 |
| 2024 | 2024-12-31 | USD 114.76B | n/a | 4.2% | 2.4 |
| 2023 | 2023-12-29 | USD 104.40B | 13.0 | 4.4% | 2.28 |
| 2022 | 2022-12-30 | USD 152.98B | 23.4 | 3.0% | 2.16 |
| 2021 | 2021-12-31 | USD 134.24B | 20.0 | 2.4% | 1.47 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 2.52 USD, yield 4.4%.
| Year | Dividends/share |
|---|---|
| FY2025 | 2.49 USD |
| FY2024 | 2.42 USD |
| FY2023 | 2.31 USD |
| FY2022 | 2.19 USD |
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma;
ETFs that hold Bristol-Myers Squibb Company
Bristol-Myers Squibb Company is one of the ten largest holdings of 18 ETFs that investors in Europe can buy. The 8 most traded of them:
| ETF | Weight | TER |
|---|---|---|
| iShares Healthcare Innovation UCITS ETF USD (Acc) | 1.56% | 0.40% |
| VanEck Morningstar US ESG Wide Moat UCITS ETF | 3.05% | 0.49% |
| iShares AI Adopters & Applications UCITS ETF USD (Acc) | 1.84% | 0.35% |
| VanEck Morningstar Global Wide Moat UCITS ETF A USD | 2.15% | 0.52% |
| WisdomTree Global Sustainable Equity UCITS ETF - USD Acc | 2.25% | 0.29% |
| WisdomTree US Equity Income UCITS ETF | 3.94% | 0.29% |
| WisdomTree US High Dividend UCITS ETF - Acc | 3.94% | 0.29% |
| L&G S&P 100 Equal Weight $ | 1.14% | 0.19% |
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Bristol-Myers Squibb Company overvalued or undervalued?
Bullrun's valuation model currently marks Bristol-Myers Squibb Company as 13.8% undervalued.
What is Bristol-Myers Squibb Company's market cap?
Bristol-Myers Squibb Company's market capitalization is USD 120.78B.
What is Bristol-Myers Squibb Company's P/E ratio?
Bristol-Myers Squibb Company's price-to-earnings (P/E) ratio is 13.0.
Does Bristol-Myers Squibb Company pay a dividend?
Bristol-Myers Squibb Company has a dividend yield of 4.4%.
What does Bristol-Myers Squibb Company do?
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications.